Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $4.4 million.

  • Praxis Precision Medicines' Other Non Operating Income fell 1015.23% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 5445.1%. This contributed to the annual value of $17.3 million for FY2024, which is 46027.13% up from last year.
  • Per Praxis Precision Medicines' latest filing, its Other Non Operating Income stood at $4.4 million for Q3 2025, which was down 1015.23% from $4.9 million recorded in Q2 2025.
  • Praxis Precision Medicines' Other Non Operating Income's 5-year high stood at $5.4 million during Q1 2025, with a 5-year trough of $132000.0 in Q1 2022.
  • For the 4-year period, Praxis Precision Medicines' Other Non Operating Income averaged around $2.4 million, with its median value being $928000.0 (2023).
  • Per our database at Business Quant, Praxis Precision Medicines' Other Non Operating Income soared by 64243.83% in 2024 and then plummeted by 1015.23% in 2025.
  • Over the past 4 years, Praxis Precision Medicines' Other Non Operating Income (Quarter) stood at $280000.0 in 2022, then soared by 231.43% to $928000.0 in 2023, then soared by 468.64% to $5.3 million in 2024, then decreased by 16.15% to $4.4 million in 2025.
  • Its Other Non Operating Income stands at $4.4 million for Q3 2025, versus $4.9 million for Q2 2025 and $5.4 million for Q1 2025.